Federated Hermes, Inc. Chimerix Inc Transaction History

Federated Hermes, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$0.9 - $1.06 $1,562 - $1,840	-1,736 Reduced 21.47%	6,350 $6,000
Q2 2023 Aug 14, 2023	SELL	$1.1 - $1.54 $735 - $1,030	-669 Reduced 7.64%	8,086 $9,000
Q1 2023 May 08, 2023	BUY	$1.19 - $2.09 $10,174 - $17,869	8,550 Added 4170.73%	8,755 $11,000
Q4 2022 Feb 13, 2023	BUY	$1.67 - $2.35 $342 - $481	205 New	205 $0
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $21,986 - $30,184	-4,204 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $184 - $271	-31 Reduced 0.73%	4,204 $26,000
Q2 2021 Aug 16, 2021	SELL	$7.54 - $9.79 $1,606 - $2,085	-213 Reduced 4.79%	4,235 $34,000
Q1 2021 May 13, 2021	BUY	$4.76 - $11.25 $21,172 - $50,040	4,448 New	4,448 $43,000
Q4 2019 Feb 14, 2020	SELL	$1.3 - $2.72 $153 - $320	-118 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $1,874 - $4,087	-971 Reduced 89.16%	118 $1,000
Q2 2018 Aug 10, 2018	BUY	$4.43 - $5.14 $748 - $868	169 Added 18.37%	1,089 $5,000
Q1 2018 May 09, 2018	BUY	$4.65 - $5.9 $3,031 - $3,846	652 Added 243.28%	920 $5,000
Q4 2017 Feb 14, 2018	BUY	$4.32 - $5.52 $1,157 - $1,479	268	268 $0

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.